Clinical rheumatology · 2026
The diagnostic value and pathological application of TREM2 in patients with osteoarthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bao Huanli, Wei Wei, Xu Chao, Huang Yuanchi, Zhang Weijie, Ma Jianbing
Аннотация
BACKGROUND: Osteoarthritis (OA) is a prevalent degenerative joint disease with limited diagnostic biomarkers. Triggering receptor expressed on myeloid cells 2 (TREM2) is a key regulator of inflammation and bone metabolism, but its role in OA remains unclear.
METHODS: Plasma and synovial fluid samples were collected from patients with OA and patients with joint trauma serving as controls. Levels of TREM2 and IL-6 were measured using RT-qPCR and ELISA. Correlation analyses were conducted to assess relationships among TREM2, IL-6, and clinical parameters. The diagnostic value of TREM2 was evaluated via receiver operating characteristic (ROC) curve analysis. Additionally, the role and regulatory mechanism of TREM2 were investigated in lipopolysaccharide (LPS)-induced chondrocytes.
RESULTS: TREM2 levels were significantly elevated in both plasma and synovial fluid of patients with OA and showed positive correlations with IL-6, Kellgren-Lawrence score and body mass index (BMI). ROC analysis revealed AUCs of 0.880 for plasma TREM2 and 0.869 for synovial fluid TREM2, with superior performance compared to IL-6 in the same cohort. Multivariate logistic regression confirmed that TREM2 remained independently associated with OA after adjusting for confounders (OR = 28.29, P = 0.006). In vitro, LPS treatment upregulated TREM2 expression in chondrocytes, which was associated with changes in cell proliferation, apoptosis, inflammatory cytokine release and oxidative stress, with preliminary evidence suggesting involvement of the NLRP3-mediated pyroptosis-associated pathway.
CONCLUSION: Elevated TREM2 in plasma and synovial fluid represents a promising exploratory biomarker for OA. In vitro findings suggest that TREM2 may modulate chondrocyte functions in association with NLRP3 inflammasome-associated molecular pathways.
METHODS: Plasma and synovial fluid samples were collected from patients with OA and patients with joint trauma serving as controls. Levels of TREM2 and IL-6 were measured using RT-qPCR and ELISA. Correlation analyses were conducted to assess relationships among TREM2, IL-6, and clinical parameters. The diagnostic value of TREM2 was evaluated via receiver operating characteristic (ROC) curve analysis. Additionally, the role and regulatory mechanism of TREM2 were investigated in lipopolysaccharide (LPS)-induced chondrocytes.
RESULTS: TREM2 levels were significantly elevated in both plasma and synovial fluid of patients with OA and showed positive correlations with IL-6, Kellgren-Lawrence score and body mass index (BMI). ROC analysis revealed AUCs of 0.880 for plasma TREM2 and 0.869 for synovial fluid TREM2, with superior performance compared to IL-6 in the same cohort. Multivariate logistic regression confirmed that TREM2 remained independently associated with OA after adjusting for confounders (OR = 28.29, P = 0.006). In vitro, LPS treatment upregulated TREM2 expression in chondrocytes, which was associated with changes in cell proliferation, apoptosis, inflammatory cytokine release and oxidative stress, with preliminary evidence suggesting involvement of the NLRP3-mediated pyroptosis-associated pathway.
CONCLUSION: Elevated TREM2 in plasma and synovial fluid represents a promising exploratory biomarker for OA. In vitro findings suggest that TREM2 may modulate chondrocyte functions in association with NLRP3 inflammasome-associated molecular pathways.